Newsroom | 14539 results

NEW YORK--(BUSINESS WIRE)--Sermo Barometer Finds Nearly Half of Physicians Report Patients are Using Non-FDA Regulated Peptides...

OSAKA, Japan--(BUSINESS WIRE)--Shionogi Announces FDA Approval of XOCOVA® (ensitrelvir), the First and Only Oral Option to Help Prevent COVID-19 Following Exposure...

SAN CARLOS, Californie--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq : ONC ; HKEX : 06160 ; SSE : 688235), une société mondiale spécialisée en oncologie, fait évoluer le paradigme thérapeutique de la leucémie lymphoïde chronique (LLC) lors du congrès annuel 2026 de l’American Society of Clinical Oncology (ASCO). Grâce à un suivi à long terme approfondi, l’étude SEQUOIA sur BRUKINSA® (zanubrutinib) renforce son rôle d’inhibiteur de BTK de référence, démontrant un contrôle durable de la maladie...

CHICAGO--(BUSINESS WIRE)--As theranostics adoption acceleratesi and radiopharmaceutical demand grows,ii healthcare systems are under increasing pressure to scale nuclear medicine operations while improving diagnostic confidence and workflow efficiency. At the 2026 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, GE HealthCare showcases its latest technologies and AI-enabled workflows to help support precision care across care pathways. Nuclear medicine is undergoing rap...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) submission for povetacicept, an investigational engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in adults with immunoglobulin A nephropathy (IgAN). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target ac...

BOSTON--(BUSINESS WIRE)--Foundation Medicine, Inc., a global, patient-focused precision medicine company, today announced that it has received approvals from the U.S. Food and Drug Administration (FDA) for FoundationOne®CDx and FoundationOne®Liquid CDx to be used as companion diagnostics for Pfizer’s TALZENNA® (talazoparib) in combination with XTANDI® (enzalutamide) to identify patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRP...

PRINCETON, N.J.--(BUSINESS WIRE)--US FDA Accepts for Priority Review Bristol Myers Squibb’s Supplemental New Drug Application for Camzyos to Treat Adolescents with oHCM...

PRINCETON, N.J.--(BUSINESS WIRE)--BMS Announces Opdivo (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma...

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its solid tumor pipeline being presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago). These data underscore the significant acceleration across the Company’s high-priority breast, gynecologic and gastrointestinal (GI) cancer development programs. Data from three differentiated Be...

加州聖卡洛斯--(BUSINESS WIRE)--(美國商業資訊)-- 在2026年美國臨床腫瘤學會(ASCO)年會上，全球性腫瘤公司BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235)正進一步推動慢性淋巴性白血病(CLL)治療典範的演進。憑藉廣泛的長期隨訪，BRUKINSA® (zanubrutinib)的SEQUOIA研究鞏固了其核心BTK抑制劑的地位，展示了在多年治療中持久的疾病控制能力。這些發現得到了真實世界證據的進一步支援，這些證據來自涵蓋超過25萬名病患的三項大型分析，彰顯了其在臨床實務中一致的療效和安全性。此外，近期獲得美國食品藥物管理局核准的BEQALZI™ (sonrotoclax)及其與BRUKINSA (ZS)聯合療法的開發，彰顯了下一代CLL有限療程治療方法的巨大潛力。 BeOne Medicines血液學醫學長Amit Agarwal, M.D.博士表示： 「CLL是一種病患需與之共處多年的疾病，衡量一種療法的真實標準在於其在漫長治療週期中的表現。我們在ASCO上發表的資料表明，BRUKINS...